中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2015, 27(4): 439-444
Toll样受体靶向药物的研究进展
钟静静,万岩岩,刁昱文,刘 兵,王竹林,靳广毅,高宁宁*
(深圳大学医学部,深圳 518060)
摘 要:Toll 样受体是一类进化上高度保守的模式识别受体,通过多种信号传递途径调节免疫系统功能,活化后可诱导多个蛋白质家族的表达,包括炎性细胞因子、I 型干扰素和趋化因子。Toll 样受体的过度活化或活化不足均会导致机体功能异常,其与免疫系统疾病、肿瘤发病机制密切相关,是个非常值得开发的新型治疗靶点。现就对目前已开发Toll 样受体药物进行了研究,对其治疗效果及临床进展做一简要综述,以期为临床预防和治疗疾病提供参考。
 
The research development of Toll-like receptors targeted drugs
ZHONG Jing-Jing, WAN Yan-Yan, DIAO Yu-Wen, LIU Bing, WANG Zhu-Lin, JIN Guang-Yi, GAO Ning-Ning*
(School of Medicine, Shenzhen University, Shenzhen 518060, China)
Abstract: Toll-like receptors are highly conserved pattern recognition receptors (PRRs). The activation of Toll can regulate the systematic immunological function and induce the expression of many protein families, including inflammation cytokines, class I interferon and chemokines. The overexpression or insufficient of TLR activation would lead to the systematic disorder. TLRs are novel potential therapy targets based on their importance in immunological disease and tumor development mechanism. We summarized the effects and clinic progresses of TLRs targeted drugs for clinical prevention and therapy.
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第3068729 位访问者,欢迎!